RARA and acute myeloid leukemia: Obviously, we have firstly to consider that ELN suggests the monitoring of MRD as part of the standards of care for AML patients and that the recommended molecular markers are the core-binding factors translocations, the NPM1 mutations and, in acute promyelocytic leukemia, the PML-RARA translocation.